Aprea Therapeutics (APRE) Insider Peters Buys 12,555 Shares

Richard Peters, an insider, recently bought 12,555 shares of Aprea Therapeutics, Inc. (NasdaqCM: APRE). This transaction happened on June 16, 2026, and reflects ongoing insider activity within the company.

Insider Buying and Selling at Aprea Therapeutics, Inc.

Apart from Richard Peters, several other insiders also made purchases on the same day. Bernd Seizinger, Rifat Pamukcu, Marc Duey, Jean-Pierre Bizzari, and Michael Grissinger each bought shares, with transactions ranging from 3,135 to 12,555 shares. None of these transactions were pre-planned under Rule 10b5-1.

Other Institutional Activity in Aprea Therapeutics

AIGH Capital Management LLC significantly increased its holdings by 645,000 shares, ending with 1,015,541 shares valued at approximately $774,757. Vestal Point Capital, LP established a new position with 350,000 shares worth $267,015. Meanwhile, Sphera Funds Management Ltd. and Nantahala Capital Management, LLC maintained their positions, with Sphera holding 270,000 shares valued at $205,983 and Nantahala holding 205,760 shares valued at $156,974. Geode Capital Management, LLC also increased its holdings by 78,181 shares, reaching a total of 119,131 shares valued at $90,890.

Aprea Therapeutics, Inc. Stock Up 2.6%

Shares of Aprea Therapeutics are trading at $0.73. The company has a market cap of approximately $9.66 million and a beta of 1.558, indicating higher volatility compared to the market. The stock's 52-week range is between $0.55 and $2.22, with a 50-day moving average of $0.85 and a 200-day moving average of $1.02. Aprea has a strong current ratio of 8.92 and a quick ratio of 8.773, suggesting solid liquidity.

Analysts Set New Price Targets

On May 14, 2026, Wedbush maintained its buy rating for Aprea Therapeutics, setting a price target of $6.00. Oppenheimer initiated coverage on May 7, 2026, with a buy rating and a $5.00 target. HC Wainwright & Co. has consistently maintained a buy rating, with targets ranging from $1.20 to $5.00 in recent months. The consensus among analysts is a strong buy, with a mean target price of $4.30 based on four analyst opinions.

About Aprea Therapeutics

Aprea Therapeutics, Inc., based in Doylestown, Pennsylvania, is a clinical-stage biopharmaceutical company. It focuses on developing novel cancer treatments that exploit synthetic lethality to target DNA damage response pathways. The company's lead product candidates include APR-1051 and ATRN-119, both in early-stage clinical trials for treating advanced solid tumors.

Bottom Line

Insider buying activity at Aprea Therapeutics, including purchases by Richard Peters and others, suggests confidence in the company's prospects. Investors often track insider transactions for potential insights into the company's future. However, it's important to note that these insider transactions do not necessarily predict future performance.